



A COMPREHENSIVE REVIEW OF ARTIFICIAL INTELLIGENCE INTEGRATION IN HEALTHCARE: OPPORTUNITIES, CHALLENGES, AND ETHICAL CONSIDERATIONS

Malyala Sanjana*

Care College of pharmacy, Oglapur, Damera Hanamkonda Telangana.



*Corresponding Author: Malyala Sanjana

Care College of pharmacy, Oglapur, Damera Hanamkonda Telangana.

Article Received on 24/03/2025

Article Revised on 14/04/2025

Article Accepted on 03/05/2025

ABSTRACT

Artificial Intelligence is rapidly transforming healthcare by improving diagnostic accuracy, enhancing treatment protocols, and streamlining administrative processes. However, its integration into healthcare systems raises significant ethical, technical, and privacy challenges. Key concerns include the authenticity of AI-generated medical references, data accessibility, and the potential for AI to exacerbate privacy breaches through electronic health records. While AI has demonstrated higher diagnostic accuracy in certain fields, its accountability in case of misdiagnosis remains a contentious issue, as AI cannot be held legally responsible like human practitioners. Furthermore, the use of biased data sets in AI models has led to concerns about social inequities, which could perpetuate discrimination in healthcare delivery. Despite these challenges, ongoing advancements in AI governance, transparency, and model explainability are crucial to addressing these concerns. This review explores the potential and limitations of AI in healthcare, with a focus on its impact on data privacy, clinical implementation, and the ethical implications in healthcare field.

KEYWORDS: Artificial intelligence, Healthcare, Precision medicine, Diagnosis and Machine learning.

INTRODUCTION

Artificial intelligence (AI) has been defined in many ways across computer science, engineering, and healthcare. Broadly, AI refers to computer programs capable of making intelligent decisions. In healthcare, AI has emerged as a valuable and reliable tool, enhancing physician practice by improving efficiency, organization, and ultimately patient outcomes. For patients, AI offers improved access to care, which may lead to greater satisfaction and better follow-up. However, like all technological advancements, AI has inherent limitations and challenges that must be carefully addressed before broader integration into healthcare systems.^[1-3] Within this broad definition, AI encompasses both systems based on predefined rules and those driven by data. This paper differentiates the two by referring to rule-based systems as automation, which is suited for well-defined, repetitive tasks. While automation has played a role in healthcare by augmenting or replacing certain human activities, its capacity for generalization and true intelligence remains limited.^[4] The focus of this research is on data-driven AI—systems that build mathematical models using prior or real-time data to support healthcare decision-making. Advances in machine learning have enabled the development of models that can successfully extract and apply meaningful knowledge from large datasets. The concept of AI dates back to the 1950s,

initially featuring simple rule-based systems following “if-then” logic. Early AI applications in healthcare struggled due to technical limitations and lacked widespread acceptance within the scientific community.^[5-7] During this period, much effort was directed toward digitizing healthcare information, developing electronic medical record systems, and building clinical informatics databases, laying the groundwork for tools like PubMed. The mid-1970s marked a turning point with the development of biomedical search engines at institutions like Rutgers and Stanford, fostering greater collaboration among universities and leading to initiatives such as the first National Institutes of Health (NIH) workshop.^[7-8] Significant milestones in AI-assisted healthcare emerged during the late 1970s, notably with the Causal-Associational Network (CASNET), a program designed to assist physicians by analyzing disease data and suggesting management strategies. Subsequent advancements included the development of diagnostic systems like MYCIN, EMYCIN, and INTERNIST-1, which expanded AI’s role in supporting primary care physicians. A major leap came in 1986 with the introduction of DXplain, a diagnostic support system that allowed physicians to input patient symptoms and receive potential diagnoses along with disease descriptions and references. DXplain originally included

500 diseases and has since expanded to cover more than 2,400. In the early 2000s, IBM's Watson further advanced AI capabilities by integrating electronic medical records and other resources to provide evidence-based clinical solutions.^[9-11] Watson's evolution broadened AI's application into new fields such as pharmacy and patient intake management. Over the past five decades, AI in medicine has transitioned from basic rule-based systems to sophisticated platforms that personalize diagnostic, therapeutic, and preventive care. These advancements have significantly improved the accuracy, consistency, and efficiency of medical practice.^[12] This article explores the transformative potential of AI in shaping the future of medicine while also acknowledging the challenges that must be overcome for its successful implementation.

AI IN PRECISION DIAGNOSTICS

Despite significant advances in medicine, effective disease diagnosis remains a global challenge due to the complexity of disease mechanisms and overlapping symptoms. Developing early diagnostic tools continues to be difficult. Artificial intelligence offers a promising solution, particularly through machine learning (ML), which uses data to enhance decision-making, manage workflows, and automate tasks cost-effectively. The accuracy of ML largely depends on the quality and quantity of input data, making it valuable in addressing diagnostic challenges.^[13] Deep learning, a subset of ML, utilizes techniques such as convolutional neural networks (CNN) and data mining to recognize patterns within large datasets, aiding in disease detection, classification, and prediction. Although still emerging, AI has shown great potential in medical diagnostics. For example, a study in the UK demonstrated that AI interpretation of mammograms reduced false positives and false negatives by 5.7% and 9.4%, respectively. Similarly, a South Korean study found that AI diagnosed breast cancer masses more accurately than radiologists (90% vs. 78%) and detected early-stage cancer at a higher rate (91% vs. 74%).^[14-16] Further, deep learning models using CNNs have successfully diagnosed melanoma cases, matching or surpassing dermatologists' accuracy. AI technologies have also been applied to detect diabetic retinopathy, identify EKG abnormalities, and predict cardiovascular risk factors. In pneumonia detection, AI algorithms achieved a sensitivity of 96% and specificity of 64%, outperforming radiologists, who recorded 50% sensitivity and 73% specificity. In another study involving 625 cases of suspected acute appendicitis, ML techniques, particularly the random forest algorithm, predicted appendicitis with an accuracy of 83.75%, precision of 84.11%, sensitivity of 81.08%, and specificity of 81.01%. These results highlight the potential of ML not only for appendicitis diagnosis but also for detecting infections like COVID-19 using patient images or blood samples. AI tools offer numerous benefits, including improved diagnostic accuracy, reduced costs, faster turnaround times, and minimized human error. They provide real-time clinical decision

support by analyzing medical images such as X-rays, CT scans, and MRIs, identifying abnormalities, fractures, tumors, and more.^[17-18]

In clinical laboratory testing—an essential component of modern healthcare—AI enhances accuracy, speed, and operational efficiency. AI applications in clinical microbiology are expanding, utilizing genomic and metagenomic data, gene sequencing, and microscopic imaging for pathogen detection and disease classification. Deep convolutional neural networks, for instance, have been effectively used for gram stain classification with high sensitivity and specificity.^[19-21] A systematic review has acknowledged the progress of ML in microorganism identification and antibiotic susceptibility testing, though challenges remain before widespread clinical adoption. In malaria diagnosis, integrating ML algorithms with digital in-line holographic microscopy (DIHM) enabled rapid and cost-effective detection of malaria-infected red blood cells without staining. Automation and AI have significantly improved laboratory efficiency in blood cultures, susceptibility testing, and molecular diagnostics, enabling faster results and more precise antibiotic selections—critical for treating infectious diseases effectively. In emergency departments (EDs), the growing disease burden, increased patient flow, and resource limitations necessitate the integration of AI technologies. AI can assist with patient triaging, reducing waiting times and enhancing patient outcomes by prioritizing critical cases. Reliable AI-driven symptom assessment tools can help streamline ED visits and optimize resource allocation.^[22]

AI IN GENOMIC MODEL

The integration of artificial intelligence with genotype analysis is revolutionizing disease surveillance, prediction, and personalized medicine. Applied at a population level, AI enables early detection of emerging health threats like COVID-19, while genomic data uncover genetic markers linked to disease susceptibility. Machine learning algorithms now make it possible to predict a wide range of phenotypes, from simple traits like eye color to complex conditions such as medication response and disease risk.^[23-24] A notable success has been the use of deep neural networks to identify genetic variants associated with autism spectrum disorder (ASD), accurately predicting ASD status based solely on genomic data. In oncology, AI-driven transcriptomic profiling has been instrumental in classifying cancers into molecular subtypes, initially for breast cancer and later extending to colorectal, ovarian, and sarcoma types—transforming approaches to diagnosis, prognosis, and treatment.^[25]

Traditional computational methods, like support vector machines and k-nearest neighbors, often struggle with batch effects and rely on limited gene sets, potentially overlooking critical biological data. However, advancements in high-throughput sequencing and AI

technologies have greatly strengthened the foundation for precision medicine and drug discovery.^[26] Despite the rich insights available from large genomic datasets, their complexity poses significant challenges for analysis. In drug discovery, AI and ML enable simultaneous assessment of genomic and clinical data to identify new therapeutic targets and opportunities for drug repurposing.^[27] Moreover, computational models are increasingly being used to predict non-clinical toxicities—such as cardiotoxicity and hepatotoxicity—which are leading causes of drug failure during clinical trials and post-market withdrawals. These predictive capabilities are essential for improving the efficiency and safety of drug development.^[28-29]

AI IN VIRTUAL PATIENT CARE

Baig et al.^[30] highlighted that the integration of wearable technology with machine learning and artificial intelligence in healthcare has already been widely explored. As a result, patient monitoring and management through virtual care, supported by intelligent and responsive wearable solutions, have become a reality and are now part of standard clinical practices. Furthermore, AI applications have demonstrated effectiveness in managing chronic conditions such as diabetes mellitus, hypertension, sleep apnea, and chronic bronchial asthma through the use of wearable, non-invasive sensors.^[31] A previous study proposed a smart sensor system based on an integrated sensor network designed to monitor individuals' home environments and collect health-related behavioral data. This system incorporates a range of unobtrusive, biomedical, and wearable sensors capable of tracking physiological parameters such as respiratory rate, pulse rate, breathing patterns, blood pressure, and electrocardiograms (ECG). Additionally, a smart device, like a tablet, was recommended to serve as an interface between the user and the sensors, with data being transmitted to the cloud for storage and further analysis to support elderly care.^[32]

In a separate case report, Patel and Tarakji^[33] described a patient in whom atrial fibrillation was successfully identified as the probable cause of her stroke after a comprehensive initial evaluation had yielded negative results. The patient had been instructed to record ECG signals using a wearable digital device, and her electrophysiologist later confirmed the findings. This case underscores the value of consumer-grade wearable devices in achieving accurate diagnoses. In the field of mental health, Sukei et al.^[34] demonstrated the potential of developing ML models capable of predicting emotional states using mobile sensor data, even when faced with large amounts of missing information. Such predictive models could serve as valuable tools for clinicians in assessing patients' mood fluctuations. However, further research is needed to address challenges related to sparse and missing tagged data, paving the way for the creation of more sophisticated and innovative predictive models.

AI IN DRUG DISCOVERY

Artificial intelligence is exceptionally well-suited for analyzing large and complex datasets in medical research. Beyond data analysis, AI aids in identifying scientific research trends, integrating diverse datasets, and accelerating drug development.^[35] Pharmaceutical companies are increasingly leveraging AI to streamline the drug discovery process. Predictive analytics enable researchers to identify suitable candidates for clinical trials and build precise models of biological systems. Machine learning enhances various stages of clinical trials, including pre-trial planning, cohort selection, participant organization, and data analysis. It also improves the patient-centered approach, generalizability, and overall success rates of clinical trials.^[36-38] However, greater attention is needed to address ML's operational and ethical challenges in this context. Natural language processing (NLP) has further demonstrated potential in improving participant management in clinical trials, though its impact on trial quality and participant experiences requires further evaluation. Additionally, generative AI can create synthetic datasets, enriching diversity and expanding the scope of clinical research. Emerging technologies like the metaverse offer new avenues for conducting trials in immersive virtual environments, fostering collaboration among geographically distant researchers. Tools like Chat GPT also play a growing role in clinical research by assisting in data collection, summarizing scientific literature, and simplifying complex medical information. While these tools enhance researchers' efficiency, they also raise important ethical considerations that need careful management.^[39-40]

In drug discovery, AI applications have evolved from machine learning, bioinformatics, and cheminformatics models, significantly reducing the cost and time involved. For example, the AI-driven "robot scientist" Eve demonstrated the ability to expedite and economize the drug development process.^[41-42] AI is predominantly used to identify candidate molecules and is expected to play an even more dynamic role in future drug discovery efforts. Several AI-driven success stories highlight its transformative potential. Toronto-based Deep Genomics, for instance, employed an AI platform to discover a novel genetic target and developed DG12P1, an oligonucleotide drug candidate for a rare form of Wilson's disease.^[43]

AI IN PATIENT ENGAGEMENT AND COMPLIANCE

Patient engagement and adherence are crucial factors influencing health outcomes and are often considered the final barrier between poor and optimal care. Non-adherence refers to a patient's failure to follow prescribed treatments or medication regimens. Studies have consistently shown that when patients are more engaged in their healthcare, outcomes improve, healthcare costs decrease, and overall patient satisfaction rises.^[44] Despite this, a survey of healthcare executives

found that fewer than half of their patients were actively involved in their treatment plans.^[45] Healthcare providers invest considerable expertise in designing treatment strategies for acute and chronic conditions. However, these efforts are often undermined if patients do not make necessary lifestyle adjustments, such as managing their weight, attending follow-up appointments, or adhering to prescribed therapies.^[44] To address this challenge, the integration of artificial intelligence in healthcare has gained momentum, aiming to enhance patient engagement. Machine learning tools and workflow engines are increasingly being utilized to deliver personalized interventions across the care continuum.^[46] Emerging research highlights the effectiveness of real-time alerts and customized educational content in promoting patient behavior change at critical moments.^[44] Furthermore, studies show that the use of healthcare applications and online patient portals can boost engagement rates by over 60%. These AI-enabled platforms allow patients to securely access, store, and share their medical information via cloud services, offering 24/7 accessibility. Some applications also provide non-emergency medical consultations, medication reminders, and follow-up alerts, thereby supporting improved adherence and better health outcomes.^[47]

AI IN REHABILITATION

Artificial intelligence is transforming rehabilitation by integrating both physical (robotics) and virtual (informatics) innovations. A key subset of AI, machine learning, focuses on developing algorithms that improve performance through experience. In rehabilitation, ML applications are advancing perioperative care, brain-computer interfaces, myoelectric control, and symbiotic neuroprosthetics.^[48-49] ML is also increasingly used in musculoskeletal rehabilitation, particularly in patient data analysis, clinical decision support, and diagnostic imaging. Technological advancements have further enhanced therapy through artificial cognitive systems capable of evaluating rehabilitation exercises based on machine-derived signals.^[50] Smart environments, such as sensor-equipped homes, assist individuals with daily tasks and alert caregivers when necessary. Wearable devices and mobile technologies now track health metrics, monitor rehabilitation progress, and support adherence to personalized recovery goals. For instance, inertial sensors in wearables can detect the quality of exercise performance, as demonstrated by a study where an Apple Watch, combined with supervised ML algorithms, achieved a 99.4% accuracy rate in classifying rotator-cuff exercises.^[51-53]

However, relying solely on wearable technology may not fully resolve adherence challenges due to the complexities associated with maintaining effective exercise routines. Complementary technologies, including physically and socially supportive robots, aid individuals recovering from injuries or neurological deficits by enhancing functional independence and well-

being. Robotic systems, including dextrous and soft robotic hands, have shown promise in mobilizing patients with musculoskeletal dysfunction, although long-term efficacy remains under investigation.^[54] Recent advancements suggest that AI-driven robotics can optimize patient movement and enhance the precision of rehabilitation exercises. Additionally, AI tools such as ChatGPT are being explored to bridge gaps in rehabilitation service delivery. ChatGPT can provide tailored exercise recommendations, monitor progress, and offer motivational feedback to support patient engagement. It can also assist patients with speech and language rehabilitation following stroke or brain injury, offering accessible and interactive therapy sessions through digital platforms.^[55]

AI IN PRECISION MEDICINE AND DOSE OPTIMIZATION

Personalized treatment, also known as precision or personalized medicine, tailors healthcare based on an individual's genetic profile, environment, lifestyle, and biomarkers.^[56] This approach aims to enhance patient outcomes by delivering more targeted, effective, and safer therapies. Artificial intelligence has become a pivotal tool in advancing personalized treatment by analyzing complex datasets, predicting outcomes, and optimizing therapeutic strategies.^[57]

Personalized treatment highlights the transformative potential of precision medicine at scale.^[59] However, delivering real-time, tailored therapeutic recommendations depends on the advancement of machine learning algorithms capable of interpreting genomic data. Pre-emptive genotyping—analyzing patient genomes before treatment becomes necessary—is key to achieving truly individualized therapy.^[58-59] AI's role in predicting treatment response has gained increasing recognition, particularly for its potential to support clinical decision-making. The model achieved over 80% prediction accuracy across multiple chemotherapy agents, underscoring AI's potential in forecasting therapeutic outcomes. Similarly, they developed AI models using electronic health records (EHR) from 17,556 patients to predict antidepressant response.^[58] Their approach minimized confounding factors and demonstrated strong predictive performance, emphasizing AI's utility in supporting personalized antidepressant selection. While these studies illustrate promising advances, further prospective and retrospective clinical research is critical to refine AI models, validate their real-world reliability, and build robust AI-based clinical decision support tools.^[56,59]

AI also plays a crucial role in optimizing drug dosing and predicting adverse drug events, thereby enhancing treatment efficacy and patient safety.^[60] One study developed an AI model to predict prothrombin time international normalized ratio (PT/INR) and optimize warfarin dosing, analyzing data from 19,719 inpatients across three institutions.^[61] The AI system outperformed

expert clinicians in predicting PT/INR values and generated reliable, individualized warfarin doses. Another innovation, CURATE.AI, is an AI-driven platform designed to dynamically personalize chemotherapy dosing based on patient-specific data. A prospective clinical trial demonstrated that CURATE.AI successfully integrated into clinical workflows, reduced chemotherapy doses, and improved patient response rates compared to standard care. These findings highlight the need for further validation through randomized clinical trials and support AI's growing role in chemotherapy optimization. Therapeutic drug monitoring (TDM) focuses on maintaining drug concentrations within a therapeutic range to maximize efficacy and minimize toxicity, especially for drugs with narrow therapeutic indices.^[62] AI has the potential to revolutionize TDM by predicting individual responses based on genetic profiles, medical history, and other relevant factors.^[63,64] Machine learning algorithms are increasingly used to predict drug-drug interactions by analyzing large patient datasets, helping prevent adverse drug reactions and improving treatment outcomes.^[65] Predictive analytics can also identify patients at high risk of drug toxicity, enabling healthcare providers to implement proactive preventive measures.^[66]

DISADVANTAGE OF AI IN HEALTHCARE

The integration of AI into healthcare has sparked significant controversy, especially regarding workforce concerns. While the aim is to make AI a cornerstone in healthcare, several challenges need to be addressed, including data accessibility, clinical implementation, and ethical dilemmas. A key issue with AI platforms like ChatGPT is the authenticity of medical references. Studies have shown that nearly half of references generated in medical articles are either fabricated or inaccurate, raising doubts about AI's reliability in this field. These concerns undermine the justification for its widespread use in medicine.^[67] Another significant ethical issue involves patient privacy, especially regarding electronic health records (EHRs). AI's involvement in managing these records could expose sensitive patient information, increasing the risk of data breaches.^[68] AI systems may extrapolate patient data into health risk probabilities, making this data more vulnerable to misuse by malicious actors. The accountability of AI in misdiagnoses also presents challenges. Although AI can outperform human doctors in some diagnoses, assigning responsibility when errors occur is difficult, as AI cannot be held legally accountable in the same way a healthcare professional can. To address these challenges, strategies such as ethical governance, model explainability, and transparency have been proposed. AI requires large, relevant datasets to function effectively, but privacy concerns prevent healthcare providers from sharing this data.^[69-70] Data breaches could compromise patient privacy, creating security risks for both patients and healthcare organizations. Furthermore, the potential impact of AI on employment in healthcare raises

concerns. While AI may improve efficiency and reduce human error, it also generates fears about job displacement, as seen in past industrial revolutions. Additionally, biases in AI systems have been linked to biased data, not the algorithms themselves.^[71]

Future Research Directions in AI for Healthcare

Research into the application of artificial intelligence in healthcare should advance across several key areas:

1. **Establishing Ethical and Legal Foundations:** Future studies must focus on building strong ethical and legal frameworks to govern AI use in healthcare. This includes developing region-specific policies that promote fairness, transparency, and accountability, while actively identifying and addressing potential biases in AI systems.
2. **Optimizing Human-AI Integration:** Research should aim to enhance collaboration between AI technologies and healthcare providers. Focus areas include creating seamless workflows that incorporate AI tools, fostering mutual trust, and ensuring clear communication. Developing training programs will also be vital to help professionals effectively interpret AI insights while preserving critical human decision-making.
3. **Prioritizing Safety and Validation:** Continuous monitoring and validation of AI tools are essential to maintain their reliability, safety, and clinical relevance. Long-term studies in real-world settings should guide the refinement of AI applications, supported by standardized protocols for performance evaluation.
4. **Strengthening Education and Training:** Expanding educational initiatives to improve AI literacy among healthcare professionals is critical. Research should develop targeted training programs that address existing knowledge gaps and equip practitioners with the skills needed for confident and effective use of AI technologies.
5. **Developing Regulatory and Governance Structures:** Future research must support the creation of comprehensive regulatory frameworks tailored to AI in healthcare. Collaboration between policymakers, regulators, developers, and healthcare providers will be key to ensuring responsible innovation and sustained oversight of AI systems.

CONCLUSION

In conclusion, while AI has the potential to significantly improve healthcare by increasing efficiency, accuracy, and accessibility, its implementation requires careful consideration. Key challenges such as data privacy, ethical concerns, and responsibility for misdiagnoses must be resolved before AI can be effectively integrated into healthcare systems. Furthermore, it is crucial to ensure that AI models are trained on diverse and representative datasets to prevent biased outcomes. AI can undoubtedly transform healthcare, but to unlock its full potential, it is essential to establish clear ethical guidelines, robust regulations, and transparency in its

application. This will help ensure that its benefits are realized while minimizing risks for both patients and healthcare professionals.

REFERENCES

1. Hamet P, Tremblay J. Artificial intelligence in medicine. *Metabolism.*, 2017; 69S: S36-S40.
2. Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. *Gastrointest Endosc.*, 2020; 92: 807-812.
3. Amisha, Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. *J Fam Med Prim Care.*, 2019; 8: 2328-2331.
4. Akyon SH, Akyon FC, Yilmaz TE. Artificial intelligence-supported web application design and development for reducing polypharmacy side effects and supporting rational drug use in geriatric patients. *Front Med.*, 2023; 10: 1029198.
5. O. Oren, B.J. Gersh, D.L. Bhatt, Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints, *Lancet Digit. Health*, 2020; 2(9): e486–e488, [https://doi.org/10.1016/S2589-7500\(20\)30160-6](https://doi.org/10.1016/S2589-7500(20)30160-6).
6. J. Bajwa, U. Munir, A. Nori, B. Williams, Artificial intelligence in healthcare: transforming the practice of medicine, *Future Healthc. J.*, 2021; 8(2): e188–e194, <https://doi.org/10.7861/fhj.2021-0095>.
7. K.B. Johnson, W. Wei, D. Weeraratne, M.E. Frisse, K. Misulis, K. Rhee K, et al., Precision medicine, AI, and the future of personalized health care, *Clin. Transl. Sci.*, 2020; 14(1): 86–93, <https://doi.org/10.1111/cts.12884>.
8. E.J. Topol, High-performance medicine: the convergence of human and artificial intelligence, *Nat. Med.*, 2019; 25(1): 44–56, <https://doi.org/10.1038/s41591-018-0300-7>.
9. Shakeel, T.; Habib, S.; Boulila, W.; Koubaa, A.; Javed, A.R.; Rizwan, M.; Gadekallu, T.R.; Sufiyan, M. A survey on COVID-19 impact in the healthcare domain: Worldwide market implementation, applications, security and privacy issues, challenges and future prospects. *Complex Intell. Syst.*, 2022; 9: 1027–1058.
10. S.M.; Lee, D. Opportunities and challenges for contactless healthcare services in the post-COVID-19 Era. *Technol. Forecast. Soc. Chang.*, 2021; 167: 120712.
11. Carroll, W.M. Digital health and new technologies. In *Nursing and Informatics for the 21st Century Embracing a DigitalWorld*, 3rd ed.; Productivity Press: New York, NY, USA, 2022; 29–48.
12. Mijwil MM, Aggarwal K. A diagnostic testing for people with appendicitis using machine learning techniques. *Multimed Tools Appl.*, 2022; 81(5): 7011–23. <https://doi.org/10.1007/s11042-022-11939-8>.
13. Undru TR, Uday U, Lakshmi JT, et al. Integrating Artificial Intelligence for Clinical and Laboratory diagnosis - a review. *Maedica (Bucur.)*, 2022; 17(2): 420–6. <https://doi.org/10.26574/maedica.2022.17.2.420>.
14. Peiffer-Smadja N, Dellièrè S, Rodriguez C, Birgand G, Lescure FX, Fourati S, et al. Machine learning in the clinical microbiology laboratory: has the time come for routine practice? *Clin Microbiol Infect.*, 2020; 26(10): 1300–9. <https://doi.org/10.1016/j.cmi.2020.02.006>.
15. Smith KP, Kang AD, Kirby JE. Automated interpretation of Blood Culture Gram Stains by Use of a deep convolutional neural network. *J Clin Microbiol.*, 2018; 56(3): e01521–17. <https://doi.org/10.1128/JCM.01521-17>.
16. Weis CV, Jutzeler CR, Borgwardt K. Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review. *Clin Microbiol Infect.*, 2020; 26(10): 1310–7. <https://doi.org/10.1016/j.cmi.2020.03.014>.
17. Go T, Kim JH, Byeon H, Lee SJ. Machine learning-based in-line holographic sensing of unstained malaria-infected red blood cells. *J Biophotonics*, 2018; 11(9): e201800101. <https://doi.org/10.1002/jbio.201800101>.
18. Smith KP, Kirby JE. Image analysis and artificial intelligence in infectious disease diagnostics. *Clin Microbiol Infect.*, 2020; 26(10): 1318–23. <https://doi.org/10.1016/j.cmi.2020.03.012>.
19. Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, et al. Consolidation of clinical Microbiology Laboratories and introduction of Transformative Technologies. *Clin Microbiol Rev.*, 2020; 33(2). <https://doi.org/10.1128/cmr.00057-19>.
20. Panch T, Szolovits P, Atun R. Artificial Intelligence, Machine Learning and Health Systems. *J Global Health*, 2018; 8(2). <https://doi.org/10.7189/jogh.08.020303>.
21. Berlyand Y, Raja AS, Dorner SC, Prabhakar AM, Sonis JD, Gottumukkala RV, et al. How artificial intelligence could transform emergency department operations. *Am J Emerg Med.*, 2018; 36(8): 1515–7. <https://doi.org/10.1016/j.ajem.2018.01.017>.
22. Widen E, Raben TG, Lello L, Hsu SDH. Machine learning prediction of biomarkers from SNPs and of Disease risk from biomarkers in the UK Biobank. *Genes (Basel)*, 2021; 12(7): 991. <https://doi.org/10.3390/genes12070991>.
23. Wang H, Avillach P. Diagnostic classification and prognostic prediction using common genetic variants in autism spectrum disorder: genotype-based Deep Learning. *JMIR Med Inf.*, 2021; 9(4). <https://doi.org/10.2196/24754>.
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci.*, 2001; 98: 10869–74. <https://doi.org/10.1073/pnas.191367098>.
25. Yersal O. Biological subtypes of breast cancer: prognostic and therapeutic implications. *World J*

- Clin Oncol., 2014; 5(3): 412–24. <https://doi.org/10.5306/wjco.v5.i3.412>.
26. eek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. *Nat Rev Genet.*, 2010; 11: 733–9. <https://doi.org/10.1038/nrg2825>.
27. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The role of AI in drug discovery: Challenges, opportunities, and strategies. *Pharmaceuticals*, 2023; 16(6): 891. <https://doi.org/10.3390/ph16060891>.
28. Tran TTV, Surya Wibowo A, Tayara H, Chong KT. Artificial Intelligence in Drug Toxicity Prediction: recent advances, Challenges, and future perspectives. *J Chem Inf Model.*, 2023; 63(9): 2628–43. <https://doi.org/10.1021/acs.jcim.3c00200>.
29. Tran TTV, Tayara H, Chong KT. Artificial Intelligence in Drug Metabolism and Excretion Prediction: recent advances, Challenges, and future perspectives. *Pharmaceutics*, 2023; 15(4): 1260. <https://doi.org/10.3390/pharmaceutics15041260>.
30. Baig, M.M.; GholamHosseini, H.; Moqem, A.A.; Mirza, F.; Lindén, M. A Systematic Review of Wearable Patient Monitoring Systems—Current Challenges and Opportunities for Clinical Adoption. *J. Med. Syst.*, 2017; 41: 115.
31. Kim, J.; Campbell, A.S.; Wang, J. Wearable non-invasive epidermal glucose sensors: A review. *Talanta*, 2018; 177: 163–170.
32. Andrea, M.; Mario, R.P.; Emanuele, F.; Sauro, L.; Filippo, P.; Sara, C.; Lorenzo, S.; Annalisa, C.; Luca, R.; Riccardo, B.; et al. A smart sensing architecture for domestic monitoring: Methodological approach and experimental validation. *Sensors*, 2018; 18: 1–22. 76.
33. Patel, D.; Tarakji, K.G. Smartwatch diagnosis of atrial fibrillation in patient with embolic stroke of unknown source: A case report. *Cardiovasc. Digit. Health J.*, 2021; 2: 84–87.
34. Sükei, E.; Norbury, A.; Perez-Rodriguez, M.M.; Olmos, P.M.; Artés, A. Predicting Emotional States Using Behavioral Markers Derived From Passively Sensed Data: Data-Driven Machine Learning Approach. *JMIR mHealth uHealth*, 2021; 9: e24465.
35. Academy of Royal Medical Colleges. Artificial Intelligence in Healthcare. 2019. Available online: https://www.aomrc.org.uk/wpcontent/uploads/2019/01/Artificial_intelligence_in_healthcare_0119.pdf
36. O'mara-Eves, A.; Thomas, J.; McNaught, J.; Miwa, M.; Ananiadou, S. Using text mining for study identification in systematic reviews: A systematic review of current approaches. *Syst. Rev.*, 2015; 4: 5.
37. Weissler, E.H.; Naumann, T.; Andersson, T.; Ranganath, R.; Elemento, O.; Luo, Y.; Freitag, D.F.; Benoit, J.; Hughes, M.C.; Khan, F.; et al. The role of machine learning in clinical research: Transforming the future of evidence generation. *Trials*, 2021; 22: 1–15.
38. Suh, I.; McKinney, T.; Siu, K.-C. Current Perspective of Metaverse Application in Medical Education, Research and Patient Care. *Virtual Worlds*, 2023; 2: 115–128.
39. Khan, R.A.; Jawaid, M.; Khan, A.R.; Sajjad, M. ChatGPT-Reshaping medical education and clinical management. *Pak. J. Med. Sci.*, 2023; 39: 7653.
40. Buvailo, A. Artificial Intelligence in Drug Discovery and Biotech: 2022 Recap and Key Trends. 2022. Available online: <https://www.biopharmatrend.com/post/615-pharmaceutical-artificial-intelligence-key-developments-in-2022/>
41. Son, W.S. Drug Discovery Enhanced by Artificial Intelligence. *Biomed. J. Sci. Tech. Res.*, 2018; 12: 8936–8938.
42. Williams, K.; Bilsland, E.; Sparkes, A.; Aubrey, W.; Young, M.; Soldatova, L.N.; De Grave, K.; Ramon, J.; de Clare, M.; Sirawaraporn, W.; et al. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases. *J. R. Soc. Interface*, 2015; 12: 20141289.
43. Mak, K.-K.; Pichika, M.R. Artificial intelligence in drug development: Present status and future prospects. *Drug Discov. Today*, 2019; 24: 773–780.
44. Davenport, T.; Kalakota, R. The potential for artificial intelligence in healthcare. *Future Healthcare J.*, 2019; 6: 94–98.
45. Davenport, T.H.; Hongsermeier, T.; Mc Cord, K.A. Using AI to Improve Electronic Health Records. *Harvard Business Review*. 2018. Available online: <https://hbr.org/2018/12/using-ai-to-improve-electronic-health-records>
46. Volpp, K.; Mohta, S. Improved Engagement Leads to Better Outcomes, But Better Tools Are Needed. *Insights Report. NEJM Catalyst*. 2016. Available online: <https://catalyst.nejm.org/patient-engagementreport-improved-engagement-leads-betteroutcomes-better-toolsneeded>
47. Hukunda, B.; Rau, A.; Upadhyay, P. Reimagining Healthcare Opportunities with Artificial Intelligence. *Infosys Navigate Your Next*. 2018. Available online: <https://www.infosys.com/industries/healthcare/features/opinions/Documents/reimagininghealthcare-opportunities.pdf>
48. Anderson, D. Artificial Intelligence and Applications in PM&R. *Am. J. Phys. Med. Rehabil.*, 2019; 98: e128–e129.
49. Luxton, D.D.; Riek, L.D. Artificial intelligence and robotics in rehabilitation. In *Handbook of Rehabilitation Psychology*; Brenner, L.A., Reid-Arndt, S.A., Elliott, T.R., Frank, R.G., Caplan, B., Eds.; American Psychological Association: Washington, DC, USA, 2019; 507–520.
50. Goldzweig, C.L.; Orshansky, G.; Paige, N.M.; Towfigh, A.A.; Haggstrom, D.A.; Miake-Lye, I.; Beroes, J.M.; Shekelle, P.G. Electronic Patient Portals: Evidence on Health Outcomes, Satisfaction, Efficiency, and Attitudes. *Ann. Intern. Med.*, 2013; 159: 677–687.

51. Sinsky, C.A.; Willard-Grace, R.; Schutzbank, A.M.; Margolius, D.; Bodenheimer, T. In Search of Joy in Practice: A Report of 23 High-Functioning Primary Care Practices. *Ann. Fam. Med.*, 2013; 11: 272–278.
52. Sinsky, C.; Colligan, L.; Li, L.; Prgomet, M.; Reynolds, M.S.; Goeders, M.L.; Westbrook, J.; Tutty, M.; Blike, G. Allocation of Physician Time in Ambulatory Practice: A Time and Motion Study in 4 Specialties. *Ann. Intern. Med.*, 2016; 165: 753–760.
53. Lin, S.; Khoo, J.; Schillinger, E. Next big thing: Integrating medical scribes into academic medical centres. *BMJ Simul. Technol. Enhanc. Learn*, 2016; 2: 27–29.
54. Choi, C.; Schwarting, W.; DelPreto, J.; Rus, D. Learning Object Grasping for Soft Robot Hands. *IEEE Robot. Autom. Lett.*, 2018; 3: 2370–2377.
55. Aggarwal, R.; Ganvir, S.S. Artificial intelligence in physiotherapy. *Physiother. J. Indian Assoc. Physiother.*, 2021; 15: 55.
56. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. *Med Oncol.*, 2022; 39(2): 120. <https://doi.org/10.1007/s12032-022-01711-1>.
57. Subramanian M, Wojtuszczyzn A, Favre L, Boughorbel S, Shan J, Letaief KB, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. *J Transl Med.*, 2020; 18(1): 472. <https://doi.org/10.1186/s12967-020-02658-5>.
58. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the future of Personalized Health Care. *Clin Transl Sci.*, 2021; 14(1): 86–93. <https://doi.org/10.1111/cts.12884>.
59. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. *Clin Pharmacol Ther.*, 2012; 92(1): 87–95. <https://doi.org/10.1038/clpt.2011.371>.
60. Martin GL, Jouganous J, Savidan R, Bellec A, Goehrs C, Benkebil M, et al. Validation of Artificial Intelligence to support the automatic coding of patient adverse drug reaction reports, using Nationwide Pharmacovigilance Data. *Drug Saf.*, 2022; 45(5): 535–48. <https://doi.org/10.1007/s40264-022-01153-8>.
61. Lee H, Kim HJ, Chang HW, Kim DJ, Mo J, Kim JE. Development of a system to support warfarin dose decisions using deep neural networks. *Sci Rep.*, 2021; 11(1): 14745. Published 2021 Jul 20. <https://doi.org/10.1038/s41598-021-94305-2>.
62. Blasiak A, Truong A, Jeit W, Tan L, Kumar KS, Tan SB, et al. PRECISE CURATE.AI: a prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. *J Clin Oncol.*, 2022; 40(16suppl): 1574–4. https://doi.org/10.1200/JCO.2022.40.16_suppl.1574.
63. Sjövall F, Lanckohr C, Bracht H. What's new in therapeutic drug monitoring of antimicrobials? *Intensive care Med.*, 2023 May 3. <https://doi.org/10.1007/s00134-023-07060-5>.
64. Partin A, Brettin TS, Zhu Y, Narykov O, Clyde A, Overbeek J, Stevens RL. Deep learning methods for drug response prediction in cancer: predominant and emerging trends. *Front Med (Lausanne).*, 2023; 10: 1086097. <https://doi.org/10.3389/fmed.2023.1086097>.
65. Zhang H, Chen Y, Li F. Predicting Anticancer Drug Response with Deep Learning constrained by signaling pathways. *Front Bioinform.*, 2021; 1: 639349. <https://doi.org/10.3389/fbinf.2021.639349>.
66. Han K, Cao P, Wang Y, Xie F, Ma J, Yu M, Wang J, Xu Y, Zhang Y, Wan J. A review of approaches for Predicting Drug-Drug interactions based on machine learning. *Front Pharmacol.*, 2022; 12: 814858. <https://doi.org/10.3389/fphar.2021.814858>.
67. Bhattacharyya M, Miller VM, Bhattacharyya D, Miller LE. High rates of fabricated and inaccurate references in ChatGPT-Generated medical content. *Cureus.*, 2023; 15: e39238.
68. Ozair FF, Jamshed N, Sharma A, Aggarwal P. Ethical issues in electronic health records: a general overview. *Perspect Clin Res.*, 2015; 6: 73-76.
69. Baowaly MK, Lin CC, Liu CL, Chen KT. Synthesizing electronic health records using improved generative adversarial networks. *J Am Med Inform Assoc.*, 2019; 26: 228-241.
70. Raman R, Kumar Nair V, Nedungadi P, Ray I, Achuthan K. Darkweb research: past, present, and future trends and mapping to sustainable development goals. *Heliyon.*, 2023; 9: e22269.
71. Hannun A, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network [published correction appears in *Nat Med.* 2019 Mar; 25(3): 530]. *Nat Med.* 2019; 25: 65-69.